| First Author | Ellinghaus U | Year | 2008 |
| Journal | Eur J Immunol | Volume | 38 |
| Issue | 8 | Pages | 2096-105 |
| PubMed ID | 18604869 | Mgi Jnum | J:138198 |
| Mgi Id | MGI:3804555 | Doi | 10.1002/eji.200838254 |
| Citation | Ellinghaus U, et al. (2008) IkappaBalpha is required for marginal zone B cell lineage development. Eur J Immunol 38(8):2096-105 |
| abstractText | Inactivation of members of the nuclear factor-kappaB (NF-kappaB) family results in the decrease or defect of marginal zone B (MZB) cells. It is not known which inhibitors of the NF-kappaB family (IkappaB) are required for MZB cell development. Here, we show that mice with B cell-specific inactivation of the main NF-kappaB inhibitor IkappaBalpha have a marked decrease of MZB cells and their presumed precursors. They exhibited increased mortality rates after blood-borne bacterial infection, indicating the importance of MZB cells for bacterial clearance. In contrast, response to T cell-dependent and -independent antigens resulted only in minor changes in immunoglobulin production. Our data demonstrate the importance of the intact NF-kappaB/IkappaBalpha pathway for proper MZB cell development. |
